UQ1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Regulatory Progress For AMT-130FDA alignment to accept a three-year Phase I/II analysis as the primary basis for an accelerated BLA creates a clear, time-bound regulatory path for AMT-130. That durable regulatory progress materially shortens pathway-to-market risk and supports investment in confirmatory trials and commercial planning.
Early Efficacy Signals For AMT-260Biological activity and tolerability in the first low-dose cohort provide early clinical de-risking for AMT-260. Persistent positive signals across cohorts would diversify uniQure’s pipeline beyond Huntington’s and hemophilia, strengthening long-term growth prospects and partnership value in neurology.
Material Equity Raise Strengthens RunwayA sizable equity offering meaningfully increases available capital, extending runway to fund late-stage filings, confirmatory trials, and manufacturing scale-up. Durable impact: reduces near-term financing pressure, supports multi-year R&D investments, and preserves ability to advance registrational programs.
Bears Say
Sustained Negative Operating Cash FlowPersistent, large negative operating cash flow reflects ongoing high burn to support trials, manufacturing and operations. Even with recent financing, recurring cash needs for multi-year gene therapy development create structural funding risk and reliance on capital markets or partner payments.
Modest Revenues With Heavy LossesRevenue is small relative to R&D and operating expenses, leaving the business structurally unprofitable and not self-funding. Dependence on partner milestones and royalties (rather than diversified product sales) makes long-term cash generation contingent on others' commercial execution.
Historical Balance-sheet VolatilityHistoric swings in equity and leverage indicate prior financing strain and potential dilution risk. Although current leverage appears manageable, past negative equity and capital-structure swings increase the probability that future program funding will require dilutive financings or onerous terms.
uniQure News
UQ1 FAQ
What was uniQure N.V.’s price range in the past 12 months?
Currently, no data Available
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is CHF2.35B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Aug 04, 2026 which is in 21 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 05, 2026. The company reported -$0.689 earnings per share for the quarter, beating the consensus estimate of -$0.701 by $0.012.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.67.
How many shares outstanding does uniQure N.V. have?
Currently, no data Available
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.689 in its last earnings report, beating expectations of -$0.701. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in CH:UQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF53.62 (― Downside)
CHF53.62 (― Downside)
Blogger Sentiment
Bullish
CH:UQ1 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth CHF778.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.49%
12-Months-Change
Fundamentals
Return on Equity
-145.81%
Trailing 12-Months
Asset Growth
28.63%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
UQ1 Stock 12 Month Forecast
Average Price Target
$53.62
Options Prices
Currently, No data available
---